Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Assets (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Assets readings, the most recent being $4.6 billion for Q4 2025.

  • On a quarterly basis, Assets rose 24.55% to $4.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.6 billion, a 24.55% increase, with the full-year FY2025 number at $4.6 billion, up 24.55% from a year prior.
  • Assets hit $4.6 billion in Q4 2025 for Neurocrine Biosciences, up from $4.3 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $4.6 billion in Q4 2025 to a low of $1.8 billion in Q1 2021.
  • Median Assets over the past 5 years was $2.7 billion (2023), compared with a mean of $2.9 billion.
  • Biggest five-year swings in Assets: increased 2.52% in 2022 and later surged 47.15% in 2024.
  • Neurocrine Biosciences' Assets stood at $2.1 billion in 2021, then increased by 14.29% to $2.4 billion in 2022, then surged by 37.27% to $3.3 billion in 2023, then rose by 14.37% to $3.7 billion in 2024, then grew by 24.55% to $4.6 billion in 2025.
  • The last three reported values for Assets were $4.6 billion (Q4 2025), $4.3 billion (Q3 2025), and $3.9 billion (Q2 2025) per Business Quant data.